Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: Potential treatment for depression

(2018) Poorna ChandraRao Yalagala et al.   JOURNAL OF LIPID RESEARCH

Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study

(2017) Anette Schrag et al.   LANCET NEUROLOGY

Oral Administration of Ethanolamine Glycerophospholipid Containing a High Level of Plasmalogen Improves Memory Impairment in Amyloid β-Infused Rats

(2017) Shinji Yamashita et al.   LIPIDS

Promising Effects of Neurorestorative Diets on Motor, Cognitive, and Gastrointestinal Dysfunction after Symptom Development in a Mouse Model of Parkinson's Disease

(2017) Paula Perez-Pardo et al.   Frontiers in Aging Neuroscience

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

(2017) Takehiko Fujino et al.   EBioMedicine

Eicosapentaenoic acid and docosahexaenoic acid increase the degradation of amyloid-β by affecting insulin-degrading enzyme

(2016) Marcus O.W. Grimm et al.   Biochemistry and Cell Biology

Mechanisms of DHA transport to the brain and potential therapy to neurodegenerative diseases

(2016) Amanda Lo Van et al.   BIOCHIMIE

Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice

(2016) Kathryn E. Hopperton et al.   Journal of Neuroinflammation

Measurement of Ether Phospholipids in Human Plasma with HPLC–ELSD and LC/ESI–MS After Hydrolysis of Plasma with Phospholipase A1

(2016) Shiro Mawatari et al.   LIPIDS

α-Synuclein dimerization in erythrocytes of Gaucher disease patients: correlation with lipid abnormalities and oxidative stress

(2016) Marina Moraitou et al.   NEUROSCIENCE LETTERS

Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice

(2016) Edith Miville-Godbout et al.   PLoS One

Neuronal Orphan G-Protein Coupled Receptor Proteins Mediate Plasmalogens-Induced Activation of ERK and Akt Signaling

(2016) Md. Shamim Hossain et al.   PLoS One

Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys

(2015) Laurent Grégoire et al.   BEHAVIOURAL BRAIN RESEARCH

Plasmalogen phospholipids protect internodal myelin from oxidative damage

(2015) Adrienne M. Luoma et al.   FREE RADICAL BIOLOGY AND MEDICINE

Biomarkers of Parkinson’s disease: Present and future

(2015) Diane B. Miller et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Biological properties of a DHA-containing structured phospholipid (AceDoPC) to target the brain

(2015) M. Lagarde et al.   PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS

Neuroinflammation in Parkinson’s disease and its potential as therapeutic target

(2015) Qinqin Wang et al.   Translational Neurodegeneration

Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine

(2014) Consuelo Gajate et al.   Anti-Cancer Agents in Medicinal Chemistry

Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson's disease

(2013) Sarah K. Abbott et al.   MOVEMENT DISORDERS

Anticancer mechanisms and clinical application of alkylphospholipids

(2012) Wim J. van Blitterswijk et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Functions of plasmalogen lipids in health and disease

(2012) Nancy E. Braverman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Plasmalogens the neglected regulatory and scavenging lipid species

(2011) Stefan Wallner et al.   CHEMISTRY AND PHYSICS OF LIPIDS

Health-related quality-of-life scales in Parkinson's disease: Critique and recommendations

(2011) Pablo Martinez-Martin et al.   MOVEMENT DISORDERS

Oxidative Stress in Parkinson's Disease

(2010) Chun Zhou et al.   Annals of the New York Academy of Sciences

Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson's disease

(2009) Charalampos Dragonas et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Plasmalogens in Biological Systems: Their Role in Oxidative Processes in Biological Membranes, their Contribution to Pathological Processes and Aging and Plasmalogen Analysis

(2009) J. Leßig et al.   CURRENT MEDICINAL CHEMISTRY

Occurrence Risk and Structure of Depression in Parkinson Disease With and Without Dementia: Results From the GEPAD Study

(2009) Oliver Riedel et al.   JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY

The epidemiology of dementia associated with Parkinson disease

(2009) Dag Aarsland et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The scientific and clinical basis for the treatment of Parkinson disease (2009)

(2009) C. W. Olanow et al.   NEUROLOGY

Cognitive impairment in 873 patients with idiopathic Parkinson's disease

(2008) O. Riedel et al.   JOURNAL OF NEUROLOGY

REM behavior disorder, hallucinations and cognitive impairment in Parkinson's disease: A two-year follow up

(2008) Elena Sinforiani et al.   MOVEMENT DISORDERS